Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAG in combination with PLD for refractory acute myeloid leukemia
ChiCTR2200060082Phase 4Recruiting
- Sponsor
- Department of Hematology, Second Affiliated Hospital of Anhui Medical University
- Start
- May 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine, cytarabine, granulocyte colony-stimulating factor and doxorubicin in acute myeloid leukemia (AML), sponsored by Department of Hematology, Second Affiliated Hospital of Anhui Medical University. Primary endpoints: Complete remission, Partial remission and 3 more. Started May 2022; status: recruiting.
02
Drugs
cladribinecytarabinegranulocyte colony-stimulating factordoxorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200060082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060082.